Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$18.58
+9.3%
$17.39
$13.53
$35.25
$1.87B2.351.49 million shs3.90 million shs
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$0.50
$0.22
$8.67
$450.52M1.25464,030 shs21,870 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$5.49
+20.1%
$4.81
$3.79
$12.36
$2.23B0.8414.29 million shs59.96 million shs
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$31.57
+4.1%
$34.33
$27.12
$60.90
$1.89B2.54975,965 shs1.48 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+9.29%+18.04%+14.48%-34.76%-24.13%
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+20.13%+30.71%+30.87%-16.69%-39.60%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
+4.09%+6.94%-3.69%-19.93%-40.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.7981 of 5 stars
4.51.00.00.01.42.50.6
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
1.7398 of 5 stars
3.21.00.00.02.51.70.6
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
4.2098 of 5 stars
4.41.00.04.42.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.00
Buy$48.75162.38% Upside
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00
N/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.33
Hold$7.6038.43% Upside
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4059.65% Upside

Current Analyst Ratings Breakdown

Latest IDRA, TWST, BEAM, and RXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $55.00
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.00
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.00
5/6/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
4/10/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.00
4/10/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$58.00 ➝ $45.00
4/8/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.58M29.39N/AN/A$12.04 per share1.54
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/A0.29$0.56 per shareN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$59.82M37.31N/AN/A$1.98 per share2.77
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$347.68M5.44N/AN/A$7.64 per share4.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$132.53M-$4.61N/AN/AN/A-41.07%-16.22%-10.94%8/5/2025 (Estimated)
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$328.07M-$1.77N/AN/AN/A-579.52%-76.56%-55.68%8/6/2025 (Estimated)
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-59.76%-32.69%-25.25%8/1/2025 (Estimated)

Latest IDRA, TWST, BEAM, and RXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million
5/5/2025Q1 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$0.904.84%N/AN/A N/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
5.69
5.69
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/A
1.56
1.56
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.04
4.35
4.35
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
12.18%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510100.56 million79.33 millionOptionable
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
3262.36 million59.21 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400406.50 million329.18 millionOptionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.92 million57.86 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$18.58 +1.58 (+9.29%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$18.66 +0.08 (+0.43%)
As of 06/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Idera Pharmaceuticals stock logo

Idera Pharmaceuticals NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$5.49 +0.92 (+20.13%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$5.56 +0.07 (+1.28%)
As of 06/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$31.57 +1.24 (+4.09%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$31.58 +0.02 (+0.05%)
As of 06/6/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.